ReviewSurgery today2020
Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas.
Review in Surgery today, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 60 citations in OpenAlex.
- Decision Modeling to Guide Management of Pancreatic IPMNs: Immediate Surgery or Initial Surveillance?Annals of surgical oncology · 2026Article
- Evaluating the Kyoto Guidelines' Worrisome Features and High-Risk Stigmata to Predict High-Grade Dysplasia and Invasive Cancer in Intraductal Papillary Mucinous Neoplasms.Annals of surgical oncology · 2026Article
- DIAGNOSIS AND MANAGEMENT OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS: A NARRATIVE REVIEW BASED ON INTERNATIONAL GUIDELINES.Arquivos de gastroenterologia · 2026Review
- Diagnostic challenges of pancreatic carcinoma presenting as acute pancreatitis: A case series and literature review.Journal of the Chinese Medical Association : JCMA · 2025Review
- Pancreatic Club Perspectives on Surgical Approach, Post-Resection Follow-Up, and Role of Endoscopic Ablation on Pancreatic Cystic Neoplasms.GE Portuguese journal of gastroenterology · 2025Review
- International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas: what is the breaking news?Hepatobiliary surgery and nutrition · 2025Article
- Article
- HOXC4 promotes proliferation of pancreatic cancer cells by increasing LDHA-mediated glycolysis.Aging · 2024Article
- A case of pseudomyxoma peritonei arising from a perforated intraductal papillary mucinous neoplasm that underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Clinical journal of gastroenterology · 2024Article
- Margin-negative minimally invasive pancreatoduodenectomy following FOLFIRINOX neoadjuvant chemotherapy in invasive intraductal papillary mucinous neoplasm of pancreas: a case report.Korean journal of clinical oncology · 2023Article
- Rare Solid Pancreatic Lesions on Cross-Sectional Imaging.Diagnostics (Basel, Switzerland) · 2023Review
- Real-Life Management of Pancreatic Cysts: Simplified Review of Current Guidelines.Journal of clinical medicine · 2023Review
- Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Challenging Diagnosis.Diagnostics (Basel, Switzerland) · 2023Review
- Intracystic papillary neoplasm diagnosis following an extended cholecystectomy: a case report … and literature review.Oxford medical case reports · 2023Article
- Rare Non-Neuroendocrine Pancreatic Tumours.Cancers · 2023Review
- Comparison of Clinical and Imaginal Features According to the Pathological Grades of Dysplasia in Branch-Duct Intraductal Papillary Mucinous Neoplasm (BD-IPMN) for Personalized Medicine.Journal of personalized medicine · 2023Article
- Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence.Cancers · 2023Review
- The tumor-to-liver ratio of the standardized uptake value is a useful FDG-PET/CT parameter for predicting malignant intraductal papillary mucinous neoplasm of the pancreas.Annals of gastroenterological surgery · 2022Article
- Natural history of intracholecystic papillary neoplasm (ICPN): a rare case of ICPN whose natural history was closely followed by ultrasound.BMC gastroenterology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current treatment strategy for intraductal papillary mucinous neoplasms (IPMNs), based on the international consensus guideline, has been accepted widely. However, reported outcomes after surgical resection for IPMN show that once the tumor progresses to invasive intraductal papillary mucinous carcinoma (IPMC), recurrence is not uncommon. The surgical treatment for IPMN is invasive and sometimes followed by complications. Therefore, the best timing for resection might be at the point when high-grade dysplasia (HGD) is evident. According to previous reports, main duct type IPMN has a high malignant potential and its surgical resection is universally accepted, whereas, the incidence of HGD/invasive IPMC in branch duct and mixed type IPMNs is thought to be lower. In addition to mural nodules and a dilated main pancreatic duct, cytology and measurement of the carcinoembryonic antigen level in the pancreatic juice might be useful to differentiate HGD/invasive IPMC from low-grade dysplasia. The nomogram proposed recently to predict the risk of HGD/invasive IPMC in IPMN patients might help surgeons decide on the best treatment strategy, depending on the patient's age and general condition. Second resection for high-risk lesions in the remnant pancreas might improve the survival of IPMN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.